Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Check out some of our latest original content that was created and distributed as part of our ongoing collaborations with IR firms and other companies.

MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) Unveils Progress on CNM-Au8(R), Eyes Potential Fast-Track FDA Approval

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), is actively advancing its lead drug candidate, CNM-Au8®. The company presented its progress at two key investor events this month, including the Q1 Virtual Investor Summit and the 37th Annual Roth Conference. At both events, Clene’s management discussed the latest achievements with CNM-Au8, a gold nanocrystal-based oral suspension that targets mitochondrial dysfunction and promotes neuronal health. The drug has shown promising results in Phase 2 trials, including significant survival benefits and delayed clinical worsening in ALS patients. Clene is now preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in the second half of 2025, aiming for potential accelerated approval.

As part of its ongoing efforts, Clene is conducting further analyses recommended by the FDA regarding neurofilament light chain (“NfL”) data, a key biomarker for ALS, in its NIH-sponsored Expanded Access Program (“EAP”). The company is collaborating with APST Research GmbH to compare NfL levels in treated ALS patients to historical controls. This analysis aims to determine whether CNM-Au8 can reduce NfL decline and to demonstrate that the rate of NfL change is associated with survival in the NIH-sponsored EAP ALS population, which would further strengthen Clene’s case for regulatory approval.

To view the full articles, visit https://ibn.fm/Nyx0v and https://ibn.fm/itzPI

About Clene Inc.
Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8 is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Clene Inc. CLNN | Leave a comment

MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Announces Key Milestones and 2024 Financial Results

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced its recent accomplishments and financial results for the year ended Dec. 31, 2024. “We remain highly focused on advancing our multiple clinical programs as we work towards achieving a number of important and potentially transformational development milestones, including top-line results in 2026 for our actively enrolling confirmatory Phase 3 placebo-controlled study evaluating HyBryte(TM) (synthetic hypericin) in the treatment of early-stage cutaneous T-cell lymphoma (‘CTCL’),” stated Christopher J. Schaber, PhD, president and chief executive officer of Soligenix. “In the second half of this year, we also anticipate reporting top-line results from our ongoing Phase 2 studies for SGX945 (dusquetide) in Behçet’s disease and SGX302 (synthetic hypericin) in mild-to-moderate psoriasis.”

To view the full press release, visit https://ibn.fm/nezZp

About Soligenix Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (“SGX301” or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (“SGX302”) into psoriasis, Soligenix’s first-in-class innate defense regulator (“IDR”) technology, dusquetide (“SGX942”) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (“SGX945”) in Behçet’s disease.

The company’s Public Health Solutions business segment includes development programs for RiVax(R), its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of Soligenix’s vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Defense Threat Reduction Agency (“DTRA”) and the Biomedical Advanced Research and Development Authority (“BARDA”).

For more information, visit the company’s website at www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Soligenix Inc. SNGX | Leave a comment

Thumzup Media Corp. (NASDAQ: TZUP) Boosts Shareholder Value with Share Buyback

  • As the social media marketing revenue stream builds toward the trillion-dollar threshold, its access to consumers in the U.S. and around the world creates a powerful tool for advertisers
  • Thumzup Media offers an increasingly popular proprietary platform for linking advertisers with social media influencers and their target audiences, democratizing the process in much the same way Uber and Airbnb revolutionized their individual markets
  • The company has more than 700 advertiser clients and expects to top 1,000 during the coming summer quarter
  • Thumzup’s recent Nasdaq uplisting, as well as its new stock share repurchase program, are both moves seen as advancing shareholder value

Social media branding and marketing innovator Thumzup (NASDAQ: TZUP) continues building, helping shareholders after its uplisting to the Nasdaq exchange, announcing recently that board members have approved a stock buyback program of up to $1 million in shares and the company has repurchased $126,507 of its common stock from the open market.

“We believe that this repurchase program reflects our confidence in Thumzup’s growth trajectory and the opportunity to deploy capital strategically,” company CEO Robert Steele stated in the news release dated March 12 (https://ibn.fm/x680k).

Thumzup’s proprietary AdTech platform helps companies simply build and administer their social media advertising campaigns while simultaneously enabling influencers to easily join an open marketing opportunity and receive payment.

“This disruptive platform has the potential to redefine the social media advertising market, much like what Uber accomplished in the transportation space and what Airbnb did to the hospitality market,” Steele wrote in a January letter to shareholders celebrating the company’s achievements during the past year and offering its outlook for 2025 (https://ibn.fm/s5pCR).

Information analysts at Datareportal noted in its Digital 2024: Global Overview Report (https://ibn.fm/6Vw4d) last year indicated that more than 5 billion social media user identities now operate actively online — an increase of more than 200 times during the past 25 years, representing a growing base for companies to target as they market their products to consumers.

Market analysts at Statista predict revenue generated by social commerce will hit the trillion-dollar mark by 2028 (https://ibn.fm/IfIwF).

Thumzup has more than 700 advertising clients and expects that number to top 1,000 this summer. The AdTech model essentially provides a platform for advertisers to buy a marketing campaign at www.thumzupmedia.com, establishing how much the company will pay for social media posts about a brand or business and how many posts it will buy.

A participating influencer with an interest in the target market can then post to friends and acquaintances about that brand or business for the established term. The posts contain a statement that they are part of a paid promotion, the influencer is notified when the promotion has completed its term, and the advertiser can easily renew it if desired, providing the potential for recurring revenue.

Cash payments are made to the influencer via Venmo or PayPal, and Thumzup collects a percentage fee for the campaign. The company is also increasing its Bitcoin holdings and leveraging its digital assets to boost shareholder value.

“Thumzup allows advertisers to pay their customers and fans cash for their posts on social media — something no other company in the market, to our knowledge, currently offers,” Steele stated. “Thumzup is focused on adding small businesses to the platform, as this is a proven strategy to get digital platforms off the ground due to shorter sales cycle and the need for new solutions small business owners face. In the United States, there are more than 33 million small businesses, and an average of 45% buy digital ads in any given year.”

For more information, visit the company’s website at www.ThumzupMedia.com.

NOTE TO INVESTORS: The latest news and updates relating to TZUP are available in the company’s newsroom at https://ibn.fm/TZUP

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Thumzup Media Corp. TZUP | Leave a comment

MissionIRNewsBreaks – Thumzup Media Corp. (NASDAQ: TZUP) Fuels Explosive Growth with Disruptive AdTech Platform

Thumzup (NASDAQ: TZUP) is leveraging its proprietary social media marketing platform, AdTech, which drives influencers to catapult the effectiveness of small-business advertising. Having achieved a growth rate of over 200% CAGR, Thumzup now serves more than 700 clients, with projections to exceed 1,000 by the next financial quarter. As social media marketing continues to grow, Thumzup’s innovative platform allows brands to easily customize campaigns and incentivizes influencer engagement with direct cash rewards, making it a disruptive force in the industry. CEO Robert Steele attributed the company’s growth as a testament to the effectiveness of its model, stating, “Our rapid growth to more than 700 advertisers, up from around 200 this time last year, is confirmation of the effectiveness of our disruptive advertising model.”

To view the full article, visit https://ibn.fm/gitMN

About Thumzup®
Thumzup Media Corporation is democratizing the multi-billion dollar social media branding and marketing industry. Its flagship product, the Thumzup platform, utilizes a robust programmatic advertiser dashboard coupled with a consumer-facing App to enable individuals to get paid cash for posting about participating advertisers on major social media outlets through the Thumzup App. The easy-to-use dashboard allows advertisers to programmatically customize their campaigns. Cash payments are made to App users/creators through PayPal and other digital payment systems.

Thumzup was featured on CBS Los Angeles and in KTLA.

NOTE TO INVESTORS: The latest news and updates relating to TZUP are available in the company’s newsroom at https://ibn.fm/TZUP

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Thumzup Media Corp. TZUP | Leave a comment

Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Delivers Significant Survival Benefits in New Analyses of Healey ALS Platform Trial Data

  • Clene’s CNM-Au8® treatment was demonstrated to improve survival in ALS patients by up to 14.8 months.
  • The findings come from a post hoc analysis of the HEALEY ALS Platform Trial, comparing CNM-Au8 to a concurrently enrolled control.
  • Strong survival benefit was observed in patients meeting the planned criteria for Clene’s upcoming Phase 3 RESTORE-ALS trial.
  • The company is preparing to submit a New Drug Application (“NDA”) to the FDA later this year for potential accelerated approval, and further regulatory discussions and a confirmatory Phase 3 trial are planned for mid-2025.

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), has released new data showing that its lead drug candidate, CNM-Au8, significantly extends survival in patients with ALS. The findings were derived from a cross-regimen post hoc analysis of long-term survival in HEALEY ALS Platform Trial participants (https://ibn.fm/EgWeb).

The study compared participants treated with CNM-Au8 30 mg (Regimen C) against those in Regimen A, which served as a large concurrent control group. Survival data was tracked over 48 months using public records and site reporting. The majority (78%) of patients in both groups received standard ALS treatments such as riluzole and edaravone, or both.

Key findings of the analysis include:

  • Patients in the CNM-Au8 30 mg group of Regimen C had a median survival of 951 days, compared to 753 days in the control group — a 6.5-month improvement. When adjusted for key variables such as baseline disease severity and biomarker levels, the restricted mean survival time (“RMST”) analysis showed a statistically significant 4.1-month increase in survival (p=0.045).
  • In patients with moderate to severe ALS, the median survival improvement was greater, rising from 589 days (Regimen A) to 951 days (a gain of 11.9 months). In this subgroup, the mortality risk was reduced by 44%, with an RMST improvement of 197 days.
  • The largest benefit was seen in patients meeting the criteria for Clene’s upcoming Phase 3 RESTORE-ALS trial. This group experienced a median survival of 1079 days, 14.8 months longer than the control group (628 days), a 49% reduction in mortality risk, and an RMST improvement of 215 days.

These results align with prior studies, including the 24-week HEALEY ALS Platform Trial double-blind period, the RESCUE-ALS trial, and Expanded Access Program data. Commenting on the findings, Merit Cudkowicz, M.D., M.Sc., Principal Investigator and sponsor of the HEALEY ALS Platform Trial, director of the Sean M. Healey & AMG Center for ALS, and executive director of the Mass General Brigham Neuroscience Institute, said, “The innovative design of the HEALEY ALS Platform Trial has enabled us to extract clear and meaningful survival data that helps make decisions about CNM-Au8 drug development.”

Clene is seeking to bring CNM-Au8 to market as soon as possible. The company is preparing to launch a confirmatory Phase 3 RESTORE-ALS trial in mid-2025, while also considering an accelerated approval pathway for CNM-Au8, following discussions with the FDA in late 2024. As part of this process, Clene will conduct additional biomarker analyses, focusing on neurofilament light chain (“NfL”) data—an important measure of ALS progression.

Rob Etherington, Clene’s President and CEO, expressed optimism about the results, stating that the survival benefit reinforces CNM-Au8’s potential to extend life for people living with ALS while also validating the company’s strategic direction as it prepares for the launch of the confirmatory Phase 3 RESTORE-ALS study in mid-2025. “We look forward to discussing these findings with the FDA as we advance toward potential commercialization,” he said.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Clene Inc. CLNN | Leave a comment

MissionIRNewsBreaks – Why Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. “Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases,” reads a recent article. “With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.”

To view the full article, visit https://ibn.fm/ClK2z

About Soligenix Inc.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (“SGX301” or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (“SGX302”) into psoriasis, Soligenix’s first-in-class innate defense regulator (“IDR”) technology, dusquetide (“SGX942”) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (“SGX945”) in Behçet’s disease.

The company’s Public Health Solutions business segment includes development programs for RiVax®, its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of Soligenix’s vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Defense Threat Reduction Agency (“DTRA”) and the Biomedical Advanced Research and Development Authority (“BARDA”).

For more information, visit the company’s website at www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Soligenix Inc. SNGX | Leave a comment

D-Wave Quantum Inc. (NYSE: QBTS) Demonstrates Quantum Supremacy on a Real-World Problem

  • D-Wave has shown quantum computational supremacy on a useful, real-world problem, a first in the industry, highlighting the potential of quantum computing for materials discovery and complex simulations beyond classical computational limits.
  • A peer-reviewed paper published in Science validates that D-Wave’s annealing quantum computer solved a magnetic materials simulation problem that is beyond the capabilities of classical supercomputers.
  • The simulation, which took minutes to solve on D-Wave’s system, would require nearly one million years and more electricity than the world’s annual consumption on a GPU-based supercomputer.
  • The Advantage2 annealing quantum computer prototype was used to achieve this milestone and is available for commercial use.

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, has confirmed a major milestone in quantum computing, demonstrating quantum computational supremacy on a practical, real-world problem. A newly published, peer-reviewed paper in Science validates that D-Wave’s annealing quantum computer outperformed a state-of-the-art classical supercomputer in simulating quantum dynamics in magnetic materials. The full study, titled “Beyond-Classical Computation in Quantum Simulation,” is available at https://ibn.fm/VEsx9.

This marks the first time quantum computing has been proven to surpass classical methods on a useful, real-world problem (https://ibn.fm/H94kF). Unlike previous claims that focused on abstract mathematical problems or random number generation, D-Wave’s work addresses computational challenges in materials science, a field with implications for medical imaging, superconductors, and electronics.

An international collaboration of scientists led by D-Wave used the company’s Advantage2 annealing quantum computer prototype to simulate quantum dynamics in programmable spin glasses—complex magnetic materials that are difficult to model using conventional methods. D-Wave compared the performance against the Frontier supercomputer at Oak Ridge National Laboratory, one of the most powerful classical supercomputers available.

The results were impressive — D-Wave’s system completed the most complex simulations in minutes. Performing the same computations on the classical supercomputer would have taken nearly one million years and consumed more electricity than the world’s total annual energy consumption.

According to Dr. Alan Baratz, CEO of D-Wave, this achievement underscores the capabilities of quantum annealing. “This is a remarkable day for quantum computing. Our demonstration of quantum computational supremacy on a useful problem is an industry first. All other claims of quantum systems outperforming classical computers have been disputed or involved random number generation of no practical value,” said Dr. Baratz. “Our achievement shows, without question, that D-Wave’s annealing quantum computers are now capable of solving useful problems beyond the reach of the world’s most powerful supercomputers. We are thrilled that D-Wave customers can use this technology today to realize tangible value from annealing quantum computers.”

The ability to accurately simulate quantum materials has broad implications. Magnetic materials play a crucial role in numerous industries, from healthcare to renewable energy. Understanding their behavior through quantum simulations could lead to breakthroughs in designing more efficient electronic components, optimizing medical imaging technologies, and improving energy storage solutions.

According to Dr. Andrew King, senior distinguished scientist at D-Wave, this research proves that D-Wave’s quantum computers can reliably solve complex materials simulation problems that could lead to discovery of new materials. “Through D-Wave’s technology, we can create and manipulate programmable quantum matter in ways that were impossible even a few years ago.”

“This is a significant milestone made possible through over 25 years of research and hardware development at D-Wave, two years of collaboration across 11 institutions worldwide, and more than 100,000 GPU and CPU hours of simulation on one of the world’s fastest supercomputers as well as computing clusters in collaborating institutions,” said Dr. Mohammad Amin, chief scientist at D-Wave. “Besides realizing Richard Feynman’s vision of simulating nature on a quantum computer, this research could open new frontiers for scientific discovery and quantum application development.”

The Advantage2 System

The study builds on earlier research published in Nature Physics (2022) and Nature (2023), which demonstrated that quantum annealing provides a computational speedup for optimization problems. These findings led to the development of Advantage2’s fast anneal feature, which played a crucial role in this latest breakthrough. D-Wave also continues to develop and advance its quantum hardware, with a current Advantage2 prototype quantum computer that is four times larger than the prototype used in this study.

D-Wave offers customers immediate access to the Advantage2 prototype quantum computer through D-Wave’s Leap™ quantum cloud service, allowing businesses and researchers to explore its capabilities today. The prototype provides substantial performance improvements from previous-generation AdvantageTM systems, including increased qubit coherence, connectivity, and energy scale, which enables higher-quality solutions to larger, more complex problems.

Industry Response

The results of the study have drawn interest from the broader scientific community. Dr. Seth Lloyd, Professor of Quantum Mechanical Engineering at MIT, commented: “Although large-scale, fully error-corrected quantum computers are years in the future, quantum annealers can probe the features of quantum systems today. In an elegant paper, the D-Wave group has used a large-scale quantum annealer to uncover patterns of entanglement in a complex quantum system that lie far beyond the reach of the most powerful classical computer.”

Other leading physicists, including Dr. Hidetoshi Nishimori (Tokyo Institute of Technology) and Dr. Juan Carrasquilla (ETH Zürich), have echoed similar sentiments, recognizing the significance of this breakthrough in advancing quantum computing research.

“This paper is not only a tour-de-force for experimental physics, it is also remarkable for the clarity of the results. The authors have addressed a problem that is regarded both as important and as very challenging to a classical computer,” said Dr. Victor Martin-Mayor, Professor of Theoretical Physics, Universidad Complutense de Madrid. “The team has shown that their quantum annealer performs better at this task than the state-of-the-art methods for classical simulation.”

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our 5,000+ qubit Advantage quantum computers, the world’s largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our Advantage and Advantage2 systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in D-Wave Quantum Inc. QBTS | Leave a comment

MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Present at BIO-Europe Spring 2025

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and contract development and manufacturing (CDMO) services, announced its participation in the BIO-Europe Spring 2025 conference from March 17-19 in Milan, Italy. The company’s leadership will meet with potential pharmaceutical partners, prospective CDMO clients, and institutional investors to showcase its innovative NanoAb pipeline and biologics manufacturing capabilities. Scinai will also exhibit its CDMO services at booth #22.

To view the full press release, visit https://ibn.fm/YRT22

About Scinai Immunotherapeutics Ltd.

Scinai is a biopharmaceutical company with two complementary business units. One is focused on in-house development of inflammation and immunology (“I&I”) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (“NanoAbs”) targeting diseases with large unmet medical needs. The second business unit is a boutique CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and preclinical and clinical trial design and execution services to early stage biotech companies. For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Scinai Immunotherapeutics Ltd. SCNI | Leave a comment

Thumzup Media (NASDAQ: TZUP) Already Tops 700 Businesses Using New Social Media Marketing Solution

  • Thumzup Media deploys a proprietary social media marketing platform branded AdTech that drives influencers to slingshot the effectiveness of small-business advertising
  • The company is maintaining growth of more than 200% CAGR, currently representing more than 700 advertiser clients, with expectations of surpassing 1,000 during the coming financial reporting quarter
  • Thumzup has now uplisted to the Nasdaq stock index drawing more attention to its growing success in the social media marketing sector, a more-than-$500 billion digital revenue stream expected to pass the trillion-dollar mark by 2028

Social media marketing has grown exponentially since the turn of the century, when some 25 million social media identities existed worldwide. Last year’s Digital 2024: Global Overview Report by DataReportal (https://ibn.fm/zfypb) found that there were now well over 5 billion active social media user identities — an increase of more than 200 times during the past 25 years, with marketing tools adapting to the growth during that time.

The report found that nearly 53% of internet users said the primary reason they use social media is to find products to purchase or inspiration for purchases. And the trend only continues to grow — market analysts at Statista predict revenue generated by social commerce will hit the trillion-dollar mark by 2028 (https://ibn.fm/iatWr).

Social media branding and marketing innovator Thumzup (NASDAQ: TZUP) recently uplisted to the NASDAQ, further building its momentum as a solution to industry growth challenges through its proprietary AdTech platform, which significantly enhances the influencer recruiting and payment process. The company now represents more than 700 advertisers and expects to pass the 1,000-advertiser threshold during this year’s Q2 period.

As social media marketing growth attempts to accelerate, it is growing more sophisticated. More brands are competing online for consumers’ attention, and consumers are evolving in terms of their behaviors and preferences (https://ibn.fm/l6Sv3). Thumzup Media’s easy-to-use dashboard allows advertisers to programmatically customize their campaign, using a consumer-facing app to facilitate cash payment to social media users based on their posting success on advertisers’ behalf.

Thumzup also recently announced plans to integrate bitcoin as an additional payment option for gig economy workers.

“Our rapid growth to more than 700 advertisers, up from around 200 this time last year, is confirmation of the effectiveness of our disruptive advertising model,” Thumzup CEO Robert Steele stated in a company news release earlier this month (https://ibn.fm/V2YZW). “We are maintaining growth of more than 200% CAGR. … We are continuously growing and redefining how brands connect with consumers. By incentivizing engagement with direct cash rewards and harnessing a vast, untapped audience, we are delivering outsized value.”

For more information, visit the company’s website at www.ThumzupMedia.com.

NOTE TO INVESTORS: The latest news and updates relating to TZUP are available in the company’s newsroom at https://ibn.fm/TZUP

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Thumzup Media Corp. TZUP | Leave a comment

MissionIRNewsBreaks – D-Wave Reports Fourth Quarter and Year-End 2024 Results

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, has announced its financial results for fourth quarter and year-end 2024, with a 128% year-over-year increase in bookings, reaching $23.9 million in bookings for the year ended December 31, 2024. The company also announced a consolidated cash balance that now exceeds $300 million.

“Every day D-Wave’s quantum technology is helping customers gain competitive advantages, discover new scientific breakthroughs, and fuel innovations that were previously unimaginable,” said Dr. Alan Baratz, CEO of D-Wave. “Our mission is unwavering – to help organizations realize the benefits of quantum computing now. With record bookings, a record cash position and an unequivocal demonstration of our quantum system outperforming classical on a real-world problem, our progress toward achieving that mission is clear.”

To review the details of D-Wave’s business performance and its latest advancements in quantum computing, view the press release: https://ibn.fm/OmqHp

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our 5,000+ qubit AdvantageTM quantum computers, the world’s largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our Advantage and Advantage2TM systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in D-Wave Quantum Inc. QBTS | Leave a comment